Former Abbott Laboratories, Executive Vice President, joins Enzymotec’s Board of Directors.

Enzymotec Ltd., a developer, manufacturer and marketer of innovative bio-active lipid ingredients, recently announced the appointment of Holger Liepmann to its Board of Directors.

Holger Liepmann held various positions at Abbott Laboratories from 1986 until his retirement in 2011. At his last position he served as Executive Vice President, Nutritional Products of Abbott Laboratories and reported to the Chief Executive Officer. In this capacity he was responsible for all aspects of Abbott Laboratories’ global nutritional business, including R&D, manufacturing, supply chain and commercial operations.

Prior to joining Abbott, he worked for Bayer AG in a variety of capacities between 1975 and 1986. Mr. Liepmann has enjoyed an international career with postings in Japan, Spain, Puerto Rico, Germany and the US.

Steve Dubin, Enzymotec’s Chairman commented, “I am thrilled to have Mr. Liepmann join our board of directors. The combination of his business knowledge, global leadership skills, and industry contacts will be valuable to the Company and our board. I believe that Mr. Liepmann’s wealth of relevant industry experience will be of great value in helping us develop and support our growth strategies and enhance our leadership positioning in our markets.”

Holger Liepmann said, “As a board member, I am excited to join such a talented and dedicated team. Enzymotec’s technology, product portfolio and focus on innovation have allowed the company to become a recognized global leader in the large and growing nutritional market. I look forward to utilizing my experience to help the Company execute its strategic growth initiatives.”

About Enzymotec

Enzymotec is a leading global supplier of specialty lipid-based products and solutions. We develop, manufacture and market innovative bio-functional lipid ingredients, as well as final products, based on sophisticated proprietary processes and technologies.

For more information, visit